6.
Tiang J, Butcher N, Cullinane C, Humbert P, Minchin R
. RNAi-mediated knock-down of arylamine N-acetyltransferase-1 expression induces E-cadherin up-regulation and cell-cell contact growth inhibition. PLoS One. 2011; 6(2):e17031.
PMC: 3036737.
DOI: 10.1371/journal.pone.0017031.
View
7.
Cao W, Chau B, Hunter R, Strnatka D, McQueen C, Erickson R
. Only low levels of exogenous N-acetyltransferase can be achieved in transgenic mice. Pharmacogenomics J. 2005; 5(4):255-61.
DOI: 10.1038/sj.tpj.6500319.
View
8.
Luca F, Bubba G, Basile M, Brdicka R, Michalodimitrakis E, Rickards O
. Multiple advantageous amino acid variants in the NAT2 gene in human populations. PLoS One. 2008; 3(9):e3136.
PMC: 2527519.
DOI: 10.1371/journal.pone.0003136.
View
9.
Wang L, Minchin R, Butcher N
. Arylamine N-acetyltransferase 1 protects against reactive oxygen species during glucose starvation: Role in the regulation of p53 stability. PLoS One. 2018; 13(3):e0193560.
PMC: 5843258.
DOI: 10.1371/journal.pone.0193560.
View
10.
Butcher N, Minchin R
. Arylamine N-acetyltransferase 1 gene regulation by androgens requires a conserved heat shock element for heat shock factor-1. Carcinogenesis. 2010; 31(5):820-6.
DOI: 10.1093/carcin/bgq042.
View
11.
Boukouvala S, Price N, Plant K, Sim E
. Structure and transcriptional regulation of the Nat2 gene encoding for the drug-metabolizing enzyme arylamine N-acetyltransferase type 2 in mice. Biochem J. 2003; 375(Pt 3):593-602.
PMC: 1223723.
DOI: 10.1042/BJ20030812.
View
12.
Barker D, Husain A, Neale J, Martini B, Zhang X, Doll M
. Functional properties of an alternative, tissue-specific promoter for human arylamine N-acetyltransferase 1. Pharmacogenet Genomics. 2006; 16(7):515-25.
PMC: 1955765.
DOI: 10.1097/01.fpc.0000215066.29342.26.
View
13.
Minchin R, Butcher N
. Trimodal distribution of arylamine N-acetyltransferase 1 mRNA in breast cancer tumors: association with overall survival and drug resistance. BMC Genomics. 2018; 19(1):513.
PMC: 6029418.
DOI: 10.1186/s12864-018-4894-4.
View
14.
Stepp M, Doll M, Samuelson D, Sanders M, States J, Hein D
. Congenic rats with higher arylamine N-acetyltransferase 2 activity exhibit greater carcinogen-induced mammary tumor susceptibility independent of carcinogen metabolism. BMC Cancer. 2017; 17(1):233.
PMC: 5374573.
DOI: 10.1186/s12885-017-3221-9.
View
15.
Liu L, Wagner C, Hanna P
. Human arylamine N-acetyltransferase 1: in vitro and intracellular inactivation by nitrosoarene metabolites of toxic and carcinogenic arylamines. Chem Res Toxicol. 2008; 21(10):2005-16.
DOI: 10.1021/tx800215h.
View
16.
Boukouvala S, Sim E
. Structural analysis of the genes for human arylamine N-acetyltransferases and characterisation of alternative transcripts. Basic Clin Pharmacol Toxicol. 2005; 96(5):343-51.
DOI: 10.1111/j.1742-7843.2005.pto_02.x.
View
17.
Ragunathan N, Dairou J, Sanfins E, Busi F, Noll C, Janel N
. Cadmium alters the biotransformation of carcinogenic aromatic amines by arylamine N-acetyltransferase xenobiotic-metabolizing enzymes: molecular, cellular, and in vivo studies. Environ Health Perspect. 2010; 118(12):1685-91.
PMC: 3002187.
DOI: 10.1289/ehp.1002334.
View
18.
Stepp M, Doll M, Carlisle S, States J, Hein D
. Genetic and small molecule inhibition of arylamine N-acetyltransferase 1 reduces anchorage-independent growth in human breast cancer cell line MDA-MB-231. Mol Carcinog. 2018; 57(4):549-558.
PMC: 5832614.
DOI: 10.1002/mc.22779.
View
19.
Pacifici G, Bencini C, Rane A
. Acetyltransferase in humans: development and tissue distribution. Pharmacology. 1986; 32(5):283-91.
DOI: 10.1159/000138181.
View
20.
Magalon H, Patin E, Austerlitz F, Hegay T, Aldashev A, Quintana-Murci L
. Population genetic diversity of the NAT2 gene supports a role of acetylation in human adaptation to farming in Central Asia. Eur J Hum Genet. 2007; 16(2):243-51.
DOI: 10.1038/sj.ejhg.5201963.
View